StreetInsider.com News Articles

Form PRE 14A 20/20 Biolabs, Inc. For: Jun 01

Mon, 01 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260601/26584484.html

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood (“MCED”) test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services (“NDS”). NDS

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Wed, 27 May 2026 08:31:00 -0400

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort

Form 8-K 20/20 Biolabs, Inc. For: May 19

Tue, 26 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260526/26550513.html

20/20 Biolabs prepares contingency plans for Ebola and Hantavirus testing

Fri, 22 May 2026 08:31:35 -0400

20/20 Biolabs Inc. (NASDAQ: AIDX) announced it is developing contingency plans to establish Ebola and Hantavirus testing capabilities in its laboratory if needed to support public health agencies during potential outbreak scenarios.

The Gaithersburg, Maryland-based company stated it would draw on experience gained during the COVID-19 pandemic, when it processed more than 400,000 clinical samples in 2021 and 2022 under contracts with Montgomery County and Maryland Departments of Health.

The company is engaging with PCR test kit developers globally to assess supply chain options and evaluating existing PCR testing equipment from its pandemic operations to determine if it can be repurposed for

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories.

Early in the COVID-19 pandemic, 20/20

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic, 20/20

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic,

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic,

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic,

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic,

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic,

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Fri, 22 May 2026 08:31:00 -0400

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed

Early in the COVID-19 pandemic,